Search Results

Deals

Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin

DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc.(Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.

February 13, 2023

·

9 min read

Deals

Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed

DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has completed the sale of substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit to Cytek for approximately USD 46.5 million.

February 28, 2023

·

6 min read

Policy

QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS

QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.

November 29, 2021

·

7 min read

Deals

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

DiaSorin S.p.A. (“DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex"; NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction.

April 12, 2021

·

18 min read

QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis

QIAGEN is responsible for product development and manufacturing, while DiaSorin is responsible for global commercialization of the new solution

April 21, 2021

·

10 min read

BioCapital

QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.

November 27, 2019

·

2 min read

Biotech Beach

DiaSorin Molecular’s Simplexa™ VZV Swab Direct Molecular Assay Gets CE Mark

DiaSorin Molecular LLC announced that it has received CE marking for its Simplexa™ VZV Swab Direct assay.

September 26, 2019

·

2 min read

Policy

DiaSorin Obtains FDA Emergency Use Authorization and BARDA Funding for SARS-CoV-2 IgG Serology Kit for COVID-19 Testing in the U.S.

DiaSorin announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration for the LIAISON® SARS-CoV-2 S1/S2 IgG test.

April 25, 2020

·

3 min read

Biotech Beach

DiaSorin Molecular Receives FDA Clearance for Simplexa™ VZV Direct Molecular Assay

DiaSorin Molecular LLC announced today that it has received FDA clearance for its new Simplexa™ VZV Direct assay for use with cerebrospinal fluid (CSF) samples.

May 30, 2019

·

1 min read

Biotech Beach

DiaSorin Molecular Introduces Three New Primer Pairs for Atypical Pneumonia

DiaSorin Molecular LLC announces the availability of three new primer pairs, or Analyte Specific Reagents (ASRs), which can be used in laboratory-developed tests (LDTs).

December 21, 2018

·

1 min read